Merrimack Pharmaceuticals, Inc. (MACK): Price and Financial Metrics
GET POWR RATINGS... FREE!
MACK Stock Price Chart Interactive Chart >
MACK Price/Volume Stats
| Current price | $11.45 | 52-week high | $13.66 |
| Prev. close | $11.41 | 52-week low | $3.00 |
| Day low | $11.32 | Volume | 115,300 |
| Day high | $11.62 | Avg. volume | 256,611 |
| 50-day MA | $11.64 | Dividend yield | N/A |
| 200-day MA | $6.66 | Market Cap | 153.54M |
Merrimack Pharmaceuticals, Inc. (MACK) Company Bio
Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. The company was founded in 1993 and is based in Cambridge, Massachusetts.
Latest MACK News From Around the Web
Below are the latest news stories about MERRIMACK PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MACK as an investment opportunity.
Merrimack Pharmaceuticals (NASDAQ:MACK) Is In A Strong Position To Grow Its BusinessWe can readily understand why investors are attracted to unprofitable companies. For example, Merrimack Pharmaceuticals... |
12 Best Performing Biotech Stocks in 2022In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […] |
Bullish Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insiders filled their treasuries with US$574k worth of stock over last yearUsually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like... |
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights PlanCAMBRIDGE, Mass., December 05, 2022--MERRIMACK PHARMACEUTICALS EXTENDS SECTION 382 NET OPERATING LOSS RIGHTS PLAN |
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and SeagenHighlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog. |
MACK Price Returns
| 1-mo | 9.46% |
| 3-mo | 200.52% |
| 6-mo | 124.95% |
| 1-year | 143.62% |
| 3-year | 246.97% |
| 5-year | 3.71% |
| YTD | -0.09% |
| 2022 | 193.09% |
| 2021 | -43.25% |
| 2020 | 118.73% |
| 2019 | -18.39% |
| 2018 | -62.34% |
Loading social stream, please wait...